TrustCore Financial Services’s Cyclerion Therapeutics CYCN Stock Holding History

TrustCore Financial Services’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$192K	Hold	14,632	–	–	0.02%	276
2022 Q3	$252K	Hold	14,632	–	–	0.02%	236
2022 Q2	$161K	Hold	14,632	–	–	0.02%	280
2022 Q1	$325K	Buy	14,632 +4,727	+48%	+$114K	0.03%	218
2021 Q4	$341K	Hold	9,905	–	–	0.04%	197
2021 Q3	$608K	Hold	9,905	–	–	0.06%	151
2021 Q2	$773K	Hold	9,905	–	–	0.08%	127
2021 Q1	$553K	Hold	9,905	–	–	0.06%	156
2020 Q4	$606K	Hold	9,905	–	–	0.08%	136
2020 Q3	$1.2M	Hold	9,905	–	–	0.18%	69
2020 Q2	$1.17M	Hold	9,905	–	–	0.2%	67
2020 Q1	$525K	Hold	9,905	–	–	0.12%	111
2019 Q4	$539K	Buy	9,905 +9,755	+6,503%	+$911K	0.1%	126
2019 Q3	$36K	Hold	150	–	–	0.01%	425
2019 Q2	$34K	Buy	+150	New	+$42.5K	0.01%	425

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TrustCore Financial Services's CYCN Position: Q4 2022 in Review

TrustCore Financial Services held its Cyclerion Therapeutics (CYCN) position steady in Q4 2022 at 14,632 shares worth $192K. The position accounts for 0.02% of the portfolio, ranked #276.

TrustCore Financial Services first reported a position in CYCN in Q2 2019 and has held it in 15 quarters since. The position peaked at $1.2M in Q3 2020. 40 funds tracked by Wall St. Rank hold CYCN as of Q4 2022.

TrustCore Financial Services held 14,632 shares of Cyclerion Therapeutics worth $192K as of Q4 2022.
TrustCore Financial Services left its Cyclerion Therapeutics share count unchanged in Q4 2022.
Cyclerion Therapeutics made up 0.02% of TrustCore Financial Services's portfolio in Q4 2022, its #276 holding.
TrustCore Financial Services first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 15 quarters since.
TrustCore Financial Services's Cyclerion Therapeutics position peaked at $1.2M in Q3 2020.
40 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.